Prevalence and Prognosis of Lynch Syndrome and Sporadic Mismatch Repair Deficiency in Endometrial Cancer

Cathalijne C B Post, Ellen Stelloo, Vincent T H B M Smit, Dina Ruano, Carli M Tops, Lisa Vermij, Tessa A Rutten, Ina M Jürgenliemk-Schulz, Ludy C H W Lutgens, Jan J Jobsen, Remi A Nout, Emma J Crosbie, Melanie E Powell, Linda Mileshkin, Alexandra Leary, Paul Bessette, Hein Putter, Stephanie M de Boer, Nanda Horeweg, Maartje Nielsen, Tom van Wezel, Tjalling Bosse, Carien L Creutzberg, Cathalijne C B Post, Ellen Stelloo, Vincent T H B M Smit, Dina Ruano, Carli M Tops, Lisa Vermij, Tessa A Rutten, Ina M Jürgenliemk-Schulz, Ludy C H W Lutgens, Jan J Jobsen, Remi A Nout, Emma J Crosbie, Melanie E Powell, Linda Mileshkin, Alexandra Leary, Paul Bessette, Hein Putter, Stephanie M de Boer, Nanda Horeweg, Maartje Nielsen, Tom van Wezel, Tjalling Bosse, Carien L Creutzberg

Abstract

Background: Standard screening of endometrial cancer (EC) for Lynch syndrome (LS) is gaining traction; however, the prognostic impact of an underlying hereditary etiology is unknown. We established the prevalence, prognosis, and subsequent primary cancer incidence of patients with LS-associated EC in relation to sporadic mismatch repair deficient (MMRd)-EC in the large combined Post Operative Radiation Therapy in Endometrial Carcinoma-1, -2, and -3 trial cohort.

Methods: After MMR-immunohistochemistry, MLH1-promoter methylation testing, and next-generation sequencing, tumors were classified into 3 groups according to the molecular cause of their MMRd-EC. Kaplan-Meier method, log-rank test, and Cox model were used for survival analysis. Competing risk analysis was used to estimate the subsequent cancer probability. All statistical tests were 2-sided.

Results: Among the 1336 ECs, 410 (30.7%) were MMRd. A total of 380 (92.7%) were fully triaged: 275 (72.4%) were MLH1-hypermethylated MMRd-ECs; 36 (9.5%) LS MMRd-ECs, and 69 (18.2%) MMRd-ECs due to other causes. Limiting screening of EC patients to 60 years or younger or to 70 years or younger would have resulted in missing 18 (50.0%) and 6 (16.7%) LS diagnoses, respectively. Five-year recurrence-free survival was 91.7% (95% confidence interval [CI] = 83.1% to 100%; hazard ratio = 0.45, 95% CI = 0.16 to 1.24, P = .12) for LS, 95.5% (95% CI = 90.7% to 100%; hazard ratio = 0.17, 95% CI = 0.05 to 0.55, P = .003) for "other" vs 78.6% (95% CI = 73.8% to 83.7%) for MLH1-hypermethylated MMRd-EC. The probability of subsequent LS-associated cancer at 10 years was 11.6% (95% CI = 0.0% to 24.7%), 1.5% (95% CI = 0.0% to 4.3%), and 7.0% (95% CI = 3.0% to 10.9%) within the LS, "other," and MLH1-hypermethylated MMRd-EC groups, respectively.

Conclusions: The LS prevalence in the Post Operative Radiation Therapy in Endometrial Carcinoma trial population was 2.8% and among MMRd-ECs was 9.5%. Patients with LS-associated ECs showed a trend towards better recurrence-free survival and higher risk for second cancers compared with patients with MLH1-hypermethylated MMRd-EC.

© The Author(s) 2021. Published by Oxford University Press.

Figures

Figure 1.
Figure 1.
Flowchart. aOne case with MLH1 promoter hypermethylation in the tumor carried a germline MLH1 variant. bInsufficient material for assay. EC = endometrial cancer; LS = Lynch syndrome; Methylation (+) = MLH1 promoter hypermethylation; Methylation (−) = no MLH1 promoter hypermethylation; MMR = mismatch repair; MMRd = mismatch repair deficient; MMRp = mismatch repair proficient; MSI = microsatellite instability; NGS = next-generation sequencing.
Figure 2.
Figure 2.
Details on the mismatch repair (MMR) protein expression according to the molecular cause of their MMR-deficient endometrial cancer (MMRd-EC). MMR protein expression was scored as following: complete loss (CL), retained (R), subclonal loss (SL), unknown/failed (UK). aThe concordance of these 2 columns shows that a 2-antibody (MSH6 and PMS2) panel is as sensitive as the full panel to detect Lynch syndrome (LS). bAll MMRd-ECs including those with insufficient material for MLH1 methylation assay (n = 27) and next-generation sequencing (n = 3).
Figure 3.
Figure 3.
Kaplan-Meier survival curves for recurrence-free survival (A) and overall survival (B) for patients with methylated mismatch repair deficient (MMRd), other MMRd and Lynch syndrome (LS) associated MMRd endometrial cancer (EC). All cases with MMRd phenotype are included in this analysis, including cases with a concurrent POLE variant affecting function (POLEmut-MMRd-EC). P values reflect 2-sided log-rank test.

References

    1. Dominguez-Valentin M, Sampson JR, Seppala TT, et al.Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database. Genet Med. 2020;22(1):15–25.
    1. Ten Broeke SW, van der Klift HM, Tops CMJ, et al.Cancer risks for PMS2-associated Lynch syndrome. J Clin Oncol. 2018;36(29):2961–2968.
    1. Lu KH, Dinh M, Kohlmann W, et al.Gynecologic cancer as a “sentinel cancer” for women with hereditary nonpolyposis colorectal cancer syndrome. Obstet Gynecol. 2005;105(3):569–574.
    1. Win AK, Lindor NM, Winship I, et al.Risks of colorectal and other cancers after endometrial cancer for women with Lynch syndrome. J Natl Cancer Inst. 2013;105(4):274–279.
    1. Stelloo E, Jansen AML, Osse EM, et al.Practical guidance for mismatch repair-deficiency testing in endometrial cancer. Ann Oncol. 2016;28(1):96–102.
    1. Goodfellow PJ, Billingsley CC, Lankes HA, et al.Combined microsatellite instability, MLH1 methylation analysis, and immunohistochemistry for Lynch syndrome screening in endometrial cancers from GOG210: an NRG Oncology and Gynecologic Oncology Group Study. J Clin Oncol. 2015;33(36):4301–4308.
    1. Geurts-Giele WR, Leenen CH, Dubbink HJ, et al.Somatic aberrations of mismatch repair genes as a cause of microsatellite-unstable cancers. J Pathol. 2014;234(4):548–559.
    1. Mensenkamp AR, Vogelaar IP, van Zelst-Stams WA, et al.Somatic mutations in MLH1 and MSH2 are a frequent cause of mismatch-repair deficiency in Lynch syndrome-like tumors. Gastroenterology. 2014;146(3):643–646. e8.
    1. Haraldsdottir S, Hampel H, Tomsic J, et al.Colon and endometrial cancers with mismatch repair deficiency can arise from somatic, rather than germline, mutations. Gastroenterology. 2014;147(6):1308–1316.e1.
    1. Cancer Genome Atlas Research Network. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67–73.
    1. Stelloo E, Nout RA, Osse EM, et al.Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer-combined analysis of the PORTEC cohorts. Clin Cancer Res. 2016;22(16):4215–4224.
    1. Leon-Castillo A, de Boer SM, Powell ME, et al.; on behalf of the TransPORTEC consortium. Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy. J Clin Oncol. 2020;38(29):3388–3397.
    1. Ott PA, Bang YJ, Piha-Paul SA, et al.T-cell-inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028. J Clin Oncol. 2019;37(4):318–327.
    1. Ramchander NC, Ryan NAJ, Walker TDJ, et al.Distinct immunological landscapes characterize inherited and sporadic mismatch repair deficient endometrial cancer. Front Immunol. 2019;10:3023.
    1. Ryan NAJ, McMahon R, Tobi S, et al.The proportion of endometrial tumours associated with Lynch syndrome (PETALS): a prospective cross-sectional study. PLoS Med. 2020;17(9):e1003263.
    1. Ryan NAJ, Glaire MA, Blake D, et al.The proportion of endometrial cancers associated with Lynch syndrome: a systematic review of the literature and meta-analysis. Genet Med. 2019;21(10):2167–2180.
    1. Hampel H, Pearlman R, de la Chapelle A, et al.Double somatic mismatch repair gene pathogenic variants as common as Lynch syndrome among endometrial cancer patients. Gynecol Oncol. 2021;160(1):161–168.
    1. Hampel H, Frankel WL, Martin E, et al.Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med. 2005;352(18):1851–1860.
    1. Nout RA, Poll-Franse LVvd, Lybeert MLM, et al.Long-term outcome and quality of life of patients with endometrial carcinoma treated with or without pelvic radiotherapy in the Post Operative Radiation Therapy in Endometrial Carcinoma 1 (PORTEC-1) trial. J Clin Oncol. 2011;29(13):1692–1700.
    1. Wortman BG, Creutzberg CL, Putter H, et al.Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy. Br J Cancer. 2018;119(9):1067–1074.
    1. de Boer SM, Powell ME, Mileshkin L, et al.Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. Lancet Oncol. 2019;20(9):1273–1285.
    1. Leon-Castillo A, Gilvazquez E, Nout R, et al.Clinicopathological and molecular characterisation of ‘multiple-classifier’ endometrial carcinomas. J Pathol. 2020;250(3):312–322.
    1. Deng G, Chen A, Hong J, et al.Methylation of CpG in a small region of the hMLH1 promoter invariably correlates with the absence of gene expression. Cancer Res. 1999;59(9):2029–2033.
    1. Jansen AML, Tops CMJ, Ruano D, et al.The complexity of screening PMS2 in DNA isolated from formalin-fixed paraffin-embedded material. Eur J Hum Genet. 2020;28(3):333–338.
    1. Cohen D, Hondelink LM, Solleveld-Westerink N, et al.Optimizing mutation and fusion detection in NSCLC by Sequential DNA and RNA sequencing. J Thorac Oncol. 2020;15(6):1000–1014.
    1. Daniel WW.Biostatistics: A Foundation for Analysis in the Health Sciences. 7th ed. New York: John Wiley & Sons; 1999.
    1. Pakish JB, Zhang Q, Chen Z, et al.Immune microenvironment in microsatellite-instable endometrial cancers: hereditary or sporadic origin matters. Clin Cancer Res. 2017;23(15):4473–4481.
    1. Liu GC, Liu RY, Yan JP, et al.The heterogeneity between lynch-associated and sporadic MMR deficiency in colorectal cancers. J Natl Cancer Inst. 2018;110(9):975–984.
    1. Haraldsdottir S, Hampel H, Wu C, et al.Patients with colorectal cancer associated with Lynch syndrome and MLH1 promoter hypermethylation have similar prognoses. Genet Med. 2016;18(9):863–868.
    1. Moller P, Seppala T, Bernstein I, et al.; Mallorca Group (). Incidence of and survival after subsequent cancers in carriers of pathogenic MMR variants with previous cancer: a report from the prospective Lynch syndrome database. Gut. 2017;66(9):1657–1664.
    1. Woolderink JM, De Bock GH, de Hullu JA, et al.Characteristics of Lynch syndrome associated ovarian cancer. Gynecol Oncol. 2018;150(2):324–330.
    1. Sjursen W, Haukanes BI, Grindedal EM, et al.Current clinical criteria for Lynch syndrome are not sensitive enough to identify MSH6 mutation carriers. J Med Genet. 2010;47(9):579–585.
    1. LaDuca H, Polley EC, Yussuf A, et al.A clinical guide to hereditary cancer panel testing: evaluation of gene-specific cancer associations and sensitivity of genetic testing criteria in a cohort of 165,000 high-risk patients. Genet Med. 2020;22(2):407–415.
    1. Ryan NAJ, Morris J, Green K, et al.Association of mismatch repair mutation with age at cancer onset in lynch syndrome: implications for stratified surveillance strategies. JAMA Oncol. 2017;3(12):1702–1706.
    1. Bonadona V, Bonaiti B, Olschwang S, et al.; French Cancer Genetics Network. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. Jama. 2011;305(22):2304–2310.
    1. Snowsill TM, Ryan NAJ, Crosbie EJ.. Cost-effectiveness of the Manchester approach to identifying Lynch syndrome in women with endometrial cancer. J Clin Med. 2020;9(6):1664.
    1. Burn J, Sheth H, Elliott F, et al.Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial. Lancet. 2020;395(10240):1855–1863.
    1. Moller P, Seppala T, Bernstein I, et al.; Mallorca Group (). Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database. Gut. 2017;66(3):464–472.
    1. Horeweg N, de Bruyn M, Nout RA, et al.Prognostic integrated image-based immune and molecular profiling in early-stage endometrial cancer. Cancer Immunol Res. 2020;8(12):1508–1519.
    1. Buchanan DD, Clendenning M, Jayasekara H, et al.Double somatic mutations as a cause of tumor mismatch repair-deficiency in population-based colorectal and endometrial cancer with Lynch-like syndrome. Cancer Res. 2017;77(13 Suppl):Abstract nr 4266.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다